Revelation Biosciences, Inc. (REVB)

NASDAQ: REVB · Real-Time Price · USD

1.010

+0.010 (1.00%)

At close: Sep 3, 2026, 4:00 PM EDT

0.9843

-0.0260 (-2.54%)

Pre-market: Sep 4, 2026, 8:20 AM EDT

Revelation Biosciences Earnings Call Transcripts

Fiscal Year 2026

Transcript

Gemini, a novel anti-inflammatory therapy, is advancing to a pivotal adaptive phase II/III trial for acute kidney injury, with FDA support for a composite endpoint and efficient study design. Strong clinical and preclinical data support broad potential, and cash runway extends into Q1 2027.

Read full transcript →